Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Q3 FY24 Earnings Presentation
34 slides from Natural Capsules's earnings presentation, February 2024
Slide 1: Cover letter to BSE: Investor Presentation
NATURAL -, ARYS OSE C4, Iso Iso vee 3oN ec &e C A p S U L E S Io er Ls Eeey BE ee) E-) Pesaran . Quality aL ELD & N EE Ma Healing AC eoreenra- ED 2 sae Ten Pe wins’ LIMITED VG- Caps CORP & REGD OFFICE: “ TRIDENT TOWERS” No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011 Phone :
Slide 2: Investor Presentation
OO NaTurAL naturalcapsules.com CAPSULES LIMITED investor Presentation BSE: 524654 FEBRUARY, 2024
Slide 3: Safe Harbor
Safe Harbor PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the INVESTOR strategies, objectives and anticipated results
Slide 4: Inside this document
Inside this document PRESENTATION INVESTOR QUARTERLY COMPANY BUSINESS HIGHLIGHTS OVERVIEW CANVAS a) Lu FINANCIAL INVESTMENT bE SUSTAINABILITY peREFORMANCE MERITS = a n Lu oi —_) n a a UO oi << [a —_) bE a Zz
Slide 5: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 6: Quarterly Updates — Q3FY24 (Consolidated)
Quarterly Updates — Q3FY24 (Consolidated) PRESENTATION REVENUES 39.98 cr EBITDA 4.72 cr ® 6.56% Q-0-Q ® -7.81% Q-0-Q INVESTOR © -12.13% Y-o0-Y © -51.14% Y-o-Y EBITDA MARGINS 11.81% PAT 1.21 cr © -184 BPS Q-0-Q ®© -22.44% Q-0-Q ® -942 BPS Y-0-Y © -76.95% Y-o0-Y a) Lu i = a rv) Lu EPS ~ 1.29 oi —_) rv
Slide 7: Management Commentary
Management Commentary PRESENTATION In Q3FY23 we faced a challenging operating environment that impacted our financial performance. Yet, amidst these challenges, we have witnessed some promising developments and maintained a steadfast focus on our strategic initiatives. INVESTOR In our capsules segme
Slide 8: CAPEX Tracker
CAPEX Tracker PRESENTATION The Company will focus on ramping up its endeavours in its API business in the coming quarters. INVESTOR Q1FY23 OVA CE) Q2FY24 Q4FY24 Q1FY25 ev aL CAPSULES * Added 1 line for * 1 line for gelatin » Completed * Commissioning ~« 1 lines for HPMC = 1 lines for HPMC gelatin ca
Slide 9: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) PRESENTATION PARTICULARS (z IN cRoREs) Q3FY23) Q2FY24 Reka 72! Q-0-Q Y-0o-Y 9MFY23 Y-o-Y INVESTOR Revenue From Operations 45.50 37.52 39.98 6.56% -12.13% 134.75 115.20 -14.51% Other Income 0.05 0.35 0.50 42.86% 900.00% 0.36 1.02 183.33% Total Income 45.
Slide 10: Company Overview
naturalcapsules.com Company Overview
Slide 11: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limite
Slide 12: Our Journey
Our Journey PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION INVESTOR CD ¢ NCL was CD ¢ Soon after, in CoD CD ¢ 2003 was an ° The coming CD * In 2005-2007, NCL Ce ¢ In 2009-2012, ED © In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acquired 5 lines NCL acquired
Slide 13: Our Journey: 2015-2018 and Going Forward
2015 - 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY Installed capacity as at Q4FY23 stands at 18 BCPA Fall in oil and commodity prices led to economic 2019 onward NCL witnessed an increase in slowdown in African countries and caused a decline in export of pharmaceutical products and demand in
Slide 14: Product Offerings
Product Offerings PRESENTATION Natural Capsules Limited manufactures a vast array INVESTOR capsules, including vegetarian capsules which they have pioneered in India. The company in now foraying into API manufacturing with complex CAPSULES APIs high-end patented technology developed in-house, under
Slide 15: Global Presence
Global Presence éx Zz = Natural Capsules exports to 30 countries across 5 continents, bringing in sizable a Ke\V=1ALOl- Mike) AALS). 4 ole)am = 2 % OF EXPORT SALES > AFRICA CIS * Algeria * Georgia an teh Volt ¢ Uzbekistan 2.22% oo - ¢ Ghana Ca OT y7 -_ CIS os i: ND eee * Nigeria MIDDLE EAST * South
Slide 16: Serving Leading Brands
Serving Leading Brands PRESENTATION With over 3 decades of experience in the pharma sector, NCL has garnered CUSTOMERS FOR MORE THAN excellent relationship with customers across 30 countries. The company Is now 10 YEARS focused on acquiring customers who deal with regulated markets. INVESTOR iy of t
Slide 17: Board of Directors
Board of Directors PRESENTATION INVESTOR Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR a lw E = a Wn lw — a) Wn a ee 4, 1) \ — < Mr. Pramod Kasat Mr. C P Rangachar Mr. S G Belapure Mrs. Jyo
Slide 18: Business Canvas
naturalcapsules.com Business Canvas
Slide 19: Capsules Segment
Capsules Segment PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, 2nd largest INVESTOR following stringent applicable ru
Slide 20: Enhancing Capacities
Enhancing Capacities PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. INVESTOR CAPSULES MANUFACTURING CAPACITY The ability to deliver faster = 38 Crores capital (IN
Slide 21: API Segment
API Segment PRESENTATION Natural Capsules Limited is now foraying into the API business segment through its subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at incorporated in 2020. The APIs that will be manufactured Tumkur, spread across INVESTOR 5 acres are,Hydrocortisone, Pre
Slide 22: API Segment (contd.)
API Segment conta) : x THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME " INR 130 Crores - planned capital a expenditure for setting up the DEXAMETHASONE O facility ms 10 MT 11 MT ¢ NCL will be the only = Planned Capacity Imports to India in FY23 manwfacturer SO worth ~
Slide 23: Production Linked Incentive (PLI) Scheme
The scheme intends to boost domestic manufacturing X of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-reliance and reduce import A committee on drug security constit
Slide 24: Focus on R&D
Focus on R&D PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company's recent entry into the API business is 2 DSIR a testament to its firm belief in R&D. Recognised state of the INVESTOR art R&D facilities R&D SPENDS & KEY AREAS O
Slide 25: naturalcapsules.c a
> naturalcapsules.c rs : \ be ¢ a
Slide 26: Sustainability
Sustainability PRESENTATION Initiatives Zero discharge facilities Solar power generation INVESTOR SUSTAINABLE SY) Solar concentrated heat generation funded by IREDA and (st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India “_—_ NCL believes in Recycling o
Slide 27: Financial Performance
naturalcapsules.com > a 4. Financi vo f -
Slide 28: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) PRESENTATION PARTICULARS (¢ IN cRoRES) FY19 FY20 FY21 FY22 FY23 INVESTOR Revenue from Operations 59.78 61.55 79.51 135.07 172.37 Other Income 1.13 0.95 0.73 1.01 0.57 Total Income 60.91 62.50 80.24 136.08 172.94 Total Operating Expenses 54.89 56.25 68.5
Slide 29: Balance Sheet Summary (Consolidated)
Balance Sheet Summary (Consolidated) PRESENTATION PARTICULARS (¢ IN CRORES) FY19 FY20 FY21 FY22 INVESTOR Total Equity (Networth) 55.49 55.62 62.10 82.98 148.25 Non Current Liabilities 1.23 1.08 1.55 34.85 73.57 Current Liabilities 17.61 17.98 33.30 46.45 66.89 Total Equity and Liability 74.33 74.68
Slide 30: Cash Flow Statement Summary (Consolidated)
Cash Flow Statement Summary (Consolidated) PRESENTATION PARTICULARS (¢ IN cRoRES) FY19 FY20 FY21 FY22 FY23 INVESTOR Cash Flow from Operating Activities 2.09 6.90 5.78 1.16 15.53 Cash Flow from Investing Activities (7.06) (5.74) (8.54) (45.88) (104.63) Cash Flow from Financing Activities 4.28 (1.18)
Slide 31: Investment Merits
naturalcapsules.com Investment Merits
Slide 32: Growth Drivers
Growth Drivers PRESENTATION uA Ip id LL INVESTOR Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in
Slide 33: Strategic Priorities
Strategic Priorities : e e e e va a ; NCL is geared to bring about bP a monumental changes in its 7 With the ongoing CAPEX, the approach towards its business. ' STRATEGIC PRIORITY > ACTIONS TAKEN " o > Company is enabling itself to . a = b h ket leader i ° Positioning the business to reduce margin °
Slide 34: Thank You
—. ~’ NATURAL naturalcapsules.com CAPSULES LIMITED Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Mr. Abhishek Mehra TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynagar II